Skip to main content
. Author manuscript; available in PMC: 2023 Aug 31.
Published in final edited form as: Cell Rep. 2023 Jun 28;42(7):112681. doi: 10.1016/j.celrep.2023.112681

Table 1.

Classification of PfCSP hmAbs used in this study

graphic file with name nihms-1920476-t0006.jpg
hmAb Preferred tetrapeptide Ig gene family Apparent avidity (nM) Two-step binder Stoichiometry (no. of binding sites) rPfCSPFL affinity (nM) rPfCSP5/3 affinity (nM) In vivo SPZ neutralization (bite challenge, Wang et al.8) References
VH VL Pep21 Pep22 Pep29 Wang et al.8; Kisalu et al.9
CIS43 NPDP 1–3 κ4–1 <0.001 1.5 – yes 7.2 15 4 high Wang et al.8; Kisalu et al.9
CIS42 NPDP 7–4–1 λ2–23 0.26 0.90 2.29 no 11.1 8 66 ND Kisalu et al.9; this study
L9 NVDP 3–33 κ1–5 6.0 0.28 – yes 11.2 22 3 high Wang et al.8
F10 NVDP 3–33 κ1–5 1.50 11.32 – no 3.4 14 4 ND Wang et al.8; this study
L48 NVDP 3–23 λ1–47 4.25 2.75 – yes 11.7 2 66 ND Wang et al.8; this study
317 NANP 3–30/33 κ1–5 1.2 0.49 <0.001 yes 12.2 2 2 high Wang et al.8; Oyen et al.10
311 NANP 3–30/33 λ1–40 4.1 3.0 <0.001 yes 15.6 4 2 moderate Wang et al.8; Oyen et al.10
mAb10 NANP 3–33 κ1–5 1.6 8.2 <0.001 no 15.2 6 42 moderate Wang et al.8; Kisalu et al.9
1210 NANP 3–30/33 κ1–5 2.2 100 0.043 no 12.9 29 600 low Wang et al.8; Imkeller et al.11
MGG4 NANP 3–30/33 κ4–1 4.28 2.72 <0.001 no 12.8 12 31 ND Tan et al.12; this study
MGU12 NANP 3–30/33 κ1–5 2.1 3.9 <0.001 no 10.8 7 90 low Wang et al.8; Tan et al.12
mAb4 NANP 3–33 κ2D-29 – 7.24 0.39 no 6.1 87 260 ND Kisalu et al.9; this study
mAb26 NANP 3–48 κ1–5 – – 5.07 no 5.2 1,100 520 ND Kisalu et al.9; this study

Top: graphic of PfCSP depicting the binding profiles of hmAbs used in this study. Schematics depict the N terminus, central repeat region (containing 1 NPDP, 4 NVDP, and 38 NANP tetrapep-tides), and the C terminus of PfCSP from 3D7 reference isolate. Bottom: hmAb name; preferred PfCSP tetrapeptide (NPDP, NVDP, NANP); VH and VL gene families; apparent avidity (nM) for 15mer peptide 21 (NPDPNANPNVDNAN), peptide 22 (NANPNVDPNANPNVD), and peptide 29 (NANPNANPNANPNAN) measured by biolayer interferometry (BLI); two-step binder determined by isothermal titration calorimetry (ITC); stoichiometry (no. of binding sites) of hmAb binding to recombinant full-length PfCSP (rPfCSPFL) by ITC; affinity for rPfCSPFL in the first binding event by ITC; affinity for a truncated rPfCSP containing 1 NPDP, 5 NANP, and 3 NVDP (rPfCSP5/3) in the first binding event by ITC. Qualitative score of in vivo sporozoite neutralization is based on mosquito bite challenge data 72 h after passive transfer of 600 μg hmAb in Wang et al.8; high neutralization: >70% sterile protection; moderate neutralization: 31%–69% sterile protection; low neutralization: <30% sterile protection. ND, not determined; “-”, undetectable. Data are representative of 2–3 independent experiments.